The WHO's call to prepare adaptable vaccines, diagnostics, and treatments for "Disease X" — a placeholder for the next unknown epidemic — was meant to be a forward-looking conversation. Instead, it reopened one of medicine's most contentious recent wounds: the COVID-era treatment debate. A Medscape comment thread beneath the article quickly filled with grievances over hydroxychloroquine, institutional trust, and what doctors should have been allowed to try.

The hydroxychloroquine debate resurfaced in full force, with supporters citing a meta-analysis of 424 studies and the COPCOV trial's reduced PCR-confirmed COVID cases, while critics countered that in vitro data and small observational studies don't meet the bar for clinical proof. The WHO's living guideline strongly recommended against hydroxychloroquine prophylaxis — yet the argument continued, fueled as much by institutional mistrust as by the science itself.

Key Takeaways:

• The central unresolved question: when multiple repurposed drugs seem plausible early in an outbreak, how should clinicians choose among them — and by what standard?
• Evidence standards themselves are contested: volume of studies vs. quality of trials (RCTs vs. observational data) remains a core divide.
• Personal anecdotes and unverified population-level claims circulated with little scrutiny, highlighting the challenge of information quality during crises.

Why it matters: As the world prepares for the next pandemic, the scientific and ethical framework for early treatment decisions remains deeply unsettled. Disease X may bring a new pathogen — but the same disputes over evidence, clinical autonomy, and institutional trust are likely to follow.